The U.K'.s Vernalis says that interim data from a pilot study of V3381 for chronic cough along with the data from a Phase IIb study in neuropathic pain convinced the developer to spike any further plans to develop the therapy. Vernalis' shares were hammered back in March after the company announced that V3381 had flunked the IIb study. Once one of the U.K.'s biggest biotech companies, repeated clinical failures have steadily chipped away at its value. Vernalis release